Top 10 Posts for 2023

As we approach the end of 2023, I want to wish you all a safe and Happy New Year. Hope this new year makes all your dreams come true, and your wishes fulfilled. Happy New Year to all my dear students.

On this last week of 2023, let’s review our top 10 viewed posts of this year:

Major Depressive Disorder:

(1) MDD Augmentation: 10 Augmentation Strategies

It is known that close to 50% of patients with major depressive episodes may not achieve remission after the trials of first-line antidepressants, and only around one-third will achieve remission. This is clinically relevant for both patients and medical professionals, as chances of remission reduce with each subsequent trial. This lecture series has discussed the ten available augmentation options for major depressive disorder.

Geriatric Psychiatry:

(2) Managing Bipolar Disorder in Elderly

Bipolar disorder can affect people of all ages, including elderly individuals. However, the symptoms and treatment of bipolar disorder in elderly people may differ from those in younger individuals. Psychiatry Education Forum Academy has summarized this clinically relevant topic in the following four chapters:

Bipolar Disorder:

(3) Bipolar Depression: Treatment Update 2023

In this lecture series, Dr. David Osser will provide a recent Update on the Management of Bipolar Depression from his Psychopharmacology Algorithm Project. Dr. David Osser is an Associate Professor of Psychiatry at Harvard Medical School at the VA Boston Healthcare System, Brockton Division, where he is the attending psychiatrist for Domiciliary Care for Homeless Veterans and is Co-Director for VA National Bipolar Disorder Telehealth Program.

Psychopharmacology Adverse Events Management:

(4) Managing Clozapine's Adverse Events

Clozapine was FDA-approved for treatment-refractory schizophrenia in 1989 and has remained the gold standard treatment since then for this indication. Despite this Clozapine is underutilized due to concerns from an adverse events standpoint. Historically the focus has been on hematologic concerns from clozapine. In the following lecture series by Psychiatry Education Forum Academy, Dr. Harvinder Singh will discuss the hematologic, cardiac, neurological, and gastro-intestinal adverse events with clozapine.

Psychopharmacology Adverse Events Management:

(5) Antipsychotics & Weight Gain: Update 2023

Understanding the impact of antipsychotic medications on weight gain is essential in providing comprehensive care for patients with mental health conditions. By staying up-to-date with the latest evidence and considerations for clinical practice, we can make informed decisions when prescribing antipsychotic medications, and minimize the risk of weight gain and its associated health consequences.

Women’s Mental Health:

(6) ADHD Medications & Breastfeeding

The journey of motherhood is a unique and beautiful experience, but it can also come with its own set of challenges. For mothers diagnosed with attention deficit hyperactivity disorder (ADHD), finding a balance between managing their symptoms and caring for their newborn can be particularly demanding. One common concern is whether it is safe to use ADHD medication while breastfeeding.

Anxiety Disorders:

(7) Can Pregabalin help with Generalized Anxiety Disorder?

Treatment-resistant GAD  is usually considered when a patient does not respond to at least 1 antidepressant at an adequate dose for an adequate duration. Psychiatry Education Forum Academy has discussed this clinically relevant topic discussing the AUGMENTATION and SWITCH options for Treatment-Resistant GAD.

FDA Updates:

(8) Zuranolone: First Oral Medication FDA Approved for Postpartum Depression

On Aug 4, 2023: Biogen announced the FDA approval of ZURZUVAE™ (Zuranolone) for Women with Postpartum Depression. Psychiatry Education Forum Academy has summarized this newly approved medication in clinically relevant discussions. 

Psychopharmacology: Basics & Beyond.

(9) How to use Transdermal Selegiline for MDD?

Monoamine Oxidase Inhibitors (MAOIs) have not only shown efficacy with treatment resistant depression, but are also found efficacious for the treatment of depression in the elderly, panic disorder, and phobias. The use of this effective antidepressant class has diminished due to safety concerns, but MAOIs should not be ignored especially transdermal Selegiline (EMSAM). Understanding the basics of transdermal selegiline is essential for treatment-resistant depression management.

Traumatic Brain Injury (TBI):

(10) Managing Cognitive Impairment after TBI

Cognitive impairment is one of the common outcomes of traumatic brain injury (TBI). TBI can cause damage to different areas of the brain, resulting in a range of cognitive deficits, such as memory problems, difficulties with attention and concentration, and executive dysfunction. Psychiatry Education Forum Academy lecture has discussed eight medication options for the management of cognitive impairment after traumatic brain injury.

Join Email Newsletter

* indicates required



This is a closed membership for medical professionals only.

  • 30+ Courses/Sections: Each chapter within these sections is of direct clinical relevance for your daily practice. 
  • Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
  • Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine.
  • Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
  • Essentials of Inpatient Psychiatry Book: All chapters from this book are included in the academy sections. 
  • Goal: is to have all important clinically relevant topics in one place for ease of access.
$ 150/YR
$ 99/YR


Email us your student information (program information and way to confirm your student status) to:

© 2024 All Rights Reserved.

Related Articles